SpaceX IPO Mints Windfalls as Intellia Trial Cuts Attacks 87%, J&J Risk Falls 53%

Crypto News

Arcadia Biosciences drew investor attention after closing a $4 million registered direct offering priced at market under Nasdaq rules. Buyers acquired 3,883,496 common shares, or pre-funded warrants, alongside Series A-1 and A-2 options priced at $1.03, with an exercise price of $0.91; proceeds are earmarked for working capital and general corporate purposes. First-quarter results were mixed: Zola coconut water volumes rose 18 percent year over year, yet total revenue slipped 8 percent to $1.1 million as a roughly $2.9 million warrant-related charge pushed the company to a $4.4 million net loss, reversing a $2.6 million profit a year earlier. Selling and administrative expenses fell to a company record low.

Enterprises scaling generative AI from pilots into production are facing sharply rising costs, according to fresh guidance from research-firm analysts. A vice-president analyst laid out ten best practices for technology leaders aiming to manage total cost of ownership without stalling business outcomes. The recommendations span balancing model accuracy, speed and price rather than defaulting to the most powerful model; building internal AI sandboxes paired with model cards; sequencing augmentation from prompt engineering to retrieval-augmented generation and fine-tuning by cost-benefit; and renegotiating per-task pricing for AI agents. Self-hosting, the analyst cautioned, often hides its largest expense in specialized talent rather than infrastructure, making disciplined governance and usage tracking central to sustainable spending.

Intellia Therapeutics released additional Phase 3 data for lonvo-z, its single-dose in vivo CRISPR candidate for hereditary angioedema, strengthening its commercialization case. In the HAELO trial, treated patients recorded an 87 percent reduction in mean monthly attacks versus placebo, with high statistical significance (p<0.0001); 62 percent remained attack-free over six months, against 11 percent on placebo. Attacks requiring on-demand treatment fell 89 percent, and moderate-to-severe attacks dropped 91 percent. No serious adverse events were reported in the treatment arm. The company began a rolling biologics license application with the FDA in April and is targeting a US launch in the first half of 2027.

SpaceX completed its initial public offering, delivering outsized gains to early backers, long-tenured employees and university endowments, not just chief executive Elon Musk. Mutual-fund manager Ron Baron, who invested in 2017 when the company was valued near $22 billion and later lent Musk $100 million, including $35 million of personal funds, ranked among the biggest winners. Hedge fund Darsana Capital Partners, invested since 2019 without selling a share, could clear more than $10 billion, while Andreessen Horowitz is reported to hold a roughly $10 billion stake. One veteran engineer saw early shares balloon to more than $28 million after splits, underscoring the leverage of long-held equity.

Belite Bio reached a regulatory inflection point by completing its rolling new drug application to the FDA for tinlarebant, an oral candidate for Stargardt disease type 1, a hereditary retinal disorder with no approved therapy and roughly 53,000 US patients. The submission, begun in April, carries Breakthrough Therapy designation and enters a 60-day filing review. In the Phase 3 DRAGON study, tinlarebant significantly slowed the growth of retinal lesions versus placebo, supporting its potential to delay disease progression. The company reported a solid balance sheet, with about $276.4 million in cash and $522.2 million in US treasuries at the end of the first quarter.

Johnson & Johnson reported a significant survival benefit from combining its bispecific antibody Talvey with Darzalex Faspro in relapsed or refractory multiple myeloma. In the 864-patient MonumenTAL-3 Phase 3 trial, the Tal-DP regimen cut the risk of disease progression or death by 72 percent and the risk of death by 53 percent versus a standard pomalidomide-based comparator. Two-year progression-free survival reached 81.3 percent for Tal-DP, against 51.2 percent for standard care, while overall response rates and deep remissions also improved markedly. The company has filed a supplemental application with the FDA and a Type II variation with European regulators to expand the combination’s use.

Taken together, these catalysts — a marquee SpaceX listing, a cluster of late-stage biotech filings and fresh discipline around AI spending — point to risk appetite concentrating in equities and private-market exits even as digital assets stay defensive. COINOTAG’s aggregate market data underscores the divergence: the Fear & Greed Index sits at 18 of 100, deep in Extreme Fear, while Bitcoin dominance holds at 70.4 percent, a level that historically squeezes altcoins and signals positioning bordering on bear-market conditions. With Bitcoin trading near $64,000 and capital rotating away from DeFi and broader blockchain risk, this week’s equity exuberance highlights how unevenly liquidity is flowing across markets.